4 hospitals allowed to use molnupiravir to treat COVID-19This handout photo obtained May 26, 2021, courtesy of Pharmaceutical company Merck shows capsules of the experimental antiviral drug Molnupiravir. FDA director general Eric Domingo said molnupiravir, an investigational antiviral drug to treat COVID-19, can now be applied for CSP with his agency. As COVID-19 cases continue to increase, the Philippine Health Insurance Corp. expanded its benefit packages for Level 1 hospitals nationwide. 2021-037, PhilHealth said claims may now be made by Level 1 hospitals for moderate COVID-19 pneumonia cases. The PhiHealth advisory noted that severe and critical COVID-19 cases shall only be reimbursed in Level 2 and Level 3 hospitals, “until further notice

Source: Philippine Star October 06, 2021 15:56 UTC